Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's AOCI?
- Protagonist Therapeutics (PTGX) reported AOCI of -$828K in Q2 2026.
- How has Protagonist Therapeutics's AOCI changed year-over-year?
- Protagonist Therapeutics's AOCI decreased by 5420.0% year-over-year, from -$15K to -$828K.
- What is the long-term trend for Protagonist Therapeutics's AOCI?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's AOCI has grown at a 87.0% compound annual growth rate (CAGR), from $28K to $641K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Protagonist Therapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude